Investigation of manufacturing processes for plasma-derived medicinal products with regard to variant Creutzfeldt-Jakob disease risk

  • Email
  • Help
Current effective version

Adopted guideline

Reference numberCPMP/BWP/5136/03
Published01/10/2004
Effective from01/10/2004
KeywordsCreutzfeldt-Jakob disease (CJD), human transmissible spongiform encephalopathies, plasma-derived medicinal products, variant CJD, blood infectivity, transmissibility
DescriptionThis document provides guidance on the investigation of manufacturing processes with regard to variant Creutzfeldt-Jakob disease (vCJD) risk.


Related content


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more